

Memphasys Investor Webinar

Memphasys Limited (ASX: MEM) (“Memphasys” or “the Company”) is pleased to invite shareholders and investors to attend an investor webinar to be held on **Wednesday, 24 June 2026 at 1.30pm AEST**.

The webinar will provide an update on the Company’s recent commercial progress, regulatory milestones and near-term growth opportunities, as Memphasys advances the global commercialisation of its Felix™ System and associated recurring cartridge revenue model.

Presenters will include:

- **David Tasker**, Chairman
- **Marjan Mikel**, Non-Executive Director and Chair of the Commercialisation Committee
- **Associate Professor Hassan Bakos**

The webinar will also include a **live Q&A session**, providing shareholders and investors with the opportunity to submit questions to the presenters.

The presentation will outline the Memphasys investment thesis, including:

- The largest commercial agreement in the Company’s history, recently signed with **Monash IVF**
- Regulatory approvals secured in Europe, Australia and key international markets
- Commercial agreements signed across Europe, MENA, Asia and Australia
- The establishment of a recurring cartridge revenue model
- Revenue already being generated across multiple markets
- Significant expansion opportunities through Monash IVF and the Company’s global reseller network
- A rich near-term sales pipeline
- A clear pathway to scaling revenue and margin expansion

Webinar details

Date: Wednesday, 24 June 2026

Time: 1.30pm AEST

Registration / access link: https://us02web.zoom.us/webinar/register/WN_qZkJHfJBTCOGF8Vuofd98g

Shareholders and investors are encouraged to attend the live webinar and participate in the Q&A session.

A recording of the webinar will be made available following the event for those unable to attend live.

Authorised by the Board of Memphasys Limited.

Ends

For further information, please contact:

Colin Jacoby

Chapter One Advisors

T: +61 433 112 936

E: cjacoby@chapteroneadvisors.com.au

About Memphasys

Memphasys Limited (ASX: MEM) is an Australian-based reproductive biotechnology company commercialising the Felix™ System, a patented bio separation technology that isolates the most viable sperm cells for human assisted reproduction.

By combining electrophoresis and size-exclusion membranes, Felix™ delivers a fast, gentle and standardised sperm selection process that enhances sperm quality and reduces laboratory time. The system replaces traditional centrifugation, which can cause cellular stress and DNA damage, offering clinicians a superior, repeatable alternative.

Memphasys' commercial strategy focuses on building contracted sales through direct and distribution-led channels, scaling production to improve margins, and establishing Felix™ as a new global standard in sperm preparation for ART procedures.

Website: www.memphasys.com

The Felix™ System is a registered trademark of Memphasys Limited. All rights reserved.